- Previous Close
9.26 - Open
9.26 - Bid 9.33 x 400
- Ask --
- Day's Range
9.26 - 9.50 - 52 Week Range
7.12 - 13.09 - Volume
252,803 - Avg. Volume
877,462 - Market Cap (intraday)
1.283B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-3.58 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.29
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
www.vir.bioRecent News: VIR
View More
Performance Overview: VIR
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIR
View MoreValuation Measures
Market Cap
1.27B
Enterprise Value
444.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.70
Price/Book (mrq)
1.02
Enterprise Value/Revenue
7.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.40%
Return on Equity (ttm)
-36.58%
Revenue (ttm)
78.62M
Net Income Avi to Common (ttm)
-533.34M
Diluted EPS (ttm)
-3.58
Balance Sheet and Cash Flow
Total Cash (mrq)
914.47M
Total Debt/Equity (mrq)
7.53%
Levered Free Cash Flow (ttm)
--
Research Analysis: VIR
View MoreCompany Insights: VIR
VIR does not have Company Insights
Research Reports: VIR
View MoreWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target